Description
1 pack = 72 tablet 80 mg
Description :
Tablets of beige color with brown inclusions and notches for division.
Composition :
1 tablet contains
active ingredient:
Marbofloxacin – 80 mg.
Auxiliary substances:
lactose, celalactose 80, povidone K 90, crospovidone, silicon dioxin colloidal, calcium legenate, dry yeast, meat flavor.
Pharmacological properties :
ATC vet classification code QJ01 – antibacterial veterinary drugs for systemic use. QJ01MA93 – Marbofloxacin.
Marbofloxacin – synthetic chemotherapeutic agent, belongs to the group of fluoroquinolones.
The preparation inhibits the activity of the enzyme DNA-girase, thus disrupting DNA replication and synthesis of cellular protein of bacteria. Marbofloxacin has a bactericidal effect against Gram-positive and Gram-negative microorganisms (Staphylococcus spp.., Escherichia coli, Salmonella typhimurium, Citrobacter freundii, Enterobacter cloacae, Serratia marcescens, Morganella morganii, Proteus spp, Klebsiella spp.., Pasteurella spp., Haemophilus spp., Moraxella spp., Pseudomonas spp.), Also against mycoplasm (Mycoplasma bovis, Mycoplasma hyopneumoniae). Marbofloxacin is not active against anaerobes, fungi, or yeast.
After taking inside dogs in the recommended dose of 2 mg / kg, Marbofloxacin is quickly absorbed and reaches a maximum plasma concentration of 1.5 mg / ml for 2:00. Bioavailability is close to 100%. Marbofloxacin binds poorly with plasma proteins (less than 10%), is well distributed in the body and in most tissues (liver, kidneys, skin, lungs, bladder, gastrointestinal tract), reaches a higher concentration than in plasma. Marbofloxacin is slowly eliminated (t½ß = 14 hours in dogs), mainly in active form with urine (2/3) and feces (1/3).
Application :
Treatment of dogs and cats in diseases of the urinary tract and respiratory system, skin and soft tissues (pyodermia of skin folds, impetigo, folliculitis, furunculosis, bacterial cellulitis) caused by microorganisms sensitive to Marbofloxacin.
Readings :
Infections of skin and soft tissues. Caused by Staphylococcus spp. (S. aureus and S. intermedius), E. coli, Pasteurella multocida and Pseudomonas aeruginosa.
Dogs:
Skin pyodermia, impetigo, folliculitis, furunculosis, bacterial cellulitis. The duration of treatment is at least 5 days and up to 40 days.
Cats:
Wounds, abscesses, phlegmons. The duration of treatment is 3-5 days.
Infections of the respiratory tract. Evoked Pasteurella multocida, Enterobacteriaceae (E. coli, Klebsiella pneumoniae), staphylococcus spp. (S. aureus, S. intermedius), Pseudomonas aeruginosa, Bordetella bronchiseptica and Streptococcus spp.
Dogs:
Duration of treatment at least 7 days and up to 21 days.
Cats: Upper respiratory tract infections. Duration of treatment: 5 days.
Urinary tract infections. Caused by Staphylococcus spp. (S. aureus and S. intermedius), Streptococcus spp, Enterobacteriaceae (E. coli, Proteus spp., Klebsiella spp., Citrobacter freundii, Enterobacter cloacae) and Pseudomonas aeruginosa.
Dogs:
Related to, and not related to, prostatitis or epididymitis. The duration of treatment is at least 10 days and up to 28 days.
Dosage :
Oral dosage : Oral.
The recommended dose is 2 mg of Marbofloxacin per 2.2 lb (1 kg) body weight per day. In order to determine the correct dose, it is necessary to accurately determine the animal’s body weight (as much as possible) to avoid an insufficient dose.
The course of treatment is:
For the treatment of skin and soft tissue diseases – 5-40 days, depending on the course of the disease;
In the treatment of diseases of the urinary tract – 10-28 days, depending on the course of the disease;
In the treatment of respiratory diseases – 7-21 days, depending on the course of the disease.
Contraindications :
Do not use animals with hypersensitivity to marbofloxacin or other fluoroquinolones, or any auxiliary substance of the drug, dogs of small and medium breeds in the first 12 months of life.
Do not use in diseases caused by fungi or yeast.
Side effect:
Sometimes there may be minor side effects, such as skin reactions, vomiting, liquid faeces, thirst, short-term increase in activity. After cessation of treatment, these symptoms disappear spontaneously and do not require interruption of therapy.
Special precautions when using:
Carefully used for young animals, high doses of some fluoroquinolones may have epileptogenic potential. It is recommended to use fluoroquinolones only in view of the results of the microbial sensitivity test.
Use of the preparation in violation of the instructions given in this short characteristic of the preparation may lead to an increase in the number of bacteria resistant to fluoroquinolones.
Use during pregnancy, lactation:
In studies on laboratory animals (rats, rabbits) there was no evidence of teratogenic, embryotoxic, or toxic effect of marbofloxacin on the mother body when used in therapeutic doses.
Interaction with other drugs, or other forms of interaction:
Fluoroquinolones are known to interact with metal cations (aluminum, calcium, magnesium, iron) during oral administration. In such cases, the bioavailability of marbofloxacin may decrease. Theophylline clearance can be significantly reduced when used simultaneously with Marbofloxacin. It is not recommended to use simultaneously with tetracyclines and macrolides.
Storage :
Dry, dark, inaccessible for children at temperatures between 45-77F (8°C and 25°C).
Shelf life – 3 years.
Shelf life of the tablet divided into two halves: 4 days.
Manufacturer: Invesa (Livisto ) / Spain
Reviews
There are no reviews yet.